Long-Term HPV16/18 Antibody Responses Following a Single Dose of Nonavalent HPV Vaccine

Published On: 21 Jul, 2023 2:30 PM | Updated On: 21 Jul, 2023 4:09 PM

Long-Term HPV16/18 Antibody Responses Following a Single Dose of Nonavalent HPV Vaccine

Simplifying logistics and reducing costs in vaccination programs worldwide is a crucial goal, and achieving this for human papillomavirus (HPV) vaccination would be highly beneficial. A phase IIa trial investigated the potential of a single dose of the Gardasil9 vaccine in maintaining stable HPV type-specific antibody responses.


The trial involved 201 healthy girls and boys aged 9 to 11 years. The participants received an initial dose of the nonavalent vaccine at the beginning of the study, followed by a delayed dose at month 24 and an optional third dose at month 30. Throughout the study, blood samples were collected at various time points, including baseline, and at 6, 12, 18, 24, and 30 months after the initial dose, in order to measure HPV type-specific antibodies. The main focus was on assessing the serum HPV16 and HPV18 antibody responses.


In both girls and boys, the geometric mean concentrations of HPV16 and HPV18 antibodies showed a consistent pattern during the study. Initially, there was an increase in antibody levels at six months following vaccination. Subsequently, there was a decline between months 6 to 12. However, from months 12 to 24, the antibody levels remained stable and consistently high, reaching levels approximately 20 times higher for HPV16 and ten times higher for HPV18 compared to baseline.


This sustained and elevated antibody response observed throughout months 12, 18, and 24 (prior to the booster dose) indicates a robust and lasting immune response to the nonavalent HPV vaccine. Notably, both HPV16 and HPV18 antibody responses exhibited an anamnestic boosting effect at the 30-month mark after the delayed booster dose administered at 24 months.


These findings suggest that a single dose of the nonavalent HPV vaccine can induce a strong and durable immune response, with antibody levels remaining elevated for an extended period. Furthermore, the delayed booster dose administered after 24 months resulted in a significant immune response boost, highlighting the potential effectiveness of this vaccination approach.


Zeng Y, et al. HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine. Pediatrics July 2023; 152 (1): e2022060301. 10.1542/peds.2022-060301

user
IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team
Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks